Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. today announced results from a post-hoc study analysis showing that adult patients with schizophrenia who were treated with Latuda® (lurasidone HCl) were more likely to achieve sustained remission over 12 months of treatment compared to patients taking Seroquel XR® (quetiapine XR). The analysis utilized remission criteria that were established by the Research in Schizophrenia Working Group in 2005.1 In addition, over the 12-month study period, patients treated with quetiapine XR discontinued at a greater rate than patients treated with LATUDA.
Help employers find you! Check out all the jobs and post your resume.
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. today announced results from a post-hoc study analysis showing that adult patients with schizophrenia who were treated with Latuda® (lurasidone HCl) were more likely to achieve sustained remission over 12 months of treatment compared to patients taking Seroquel XR® (quetiapine XR). The analysis utilized remission criteria that were established by the Research in Schizophrenia Working Group in 2005.1 In addition, over the 12-month study period, patients treated with quetiapine XR discontinued at a greater rate than patients treated with LATUDA.
Help employers find you! Check out all the jobs and post your resume.
